With Cancer Vaccines in Play, Will Investors Continue to Buy-In?

TheMarketFinancial submits:The biotech universe has been a hot investment option towards the end of the year for those looking for high risk high reward equities. This industry offers investors a chance to find companies where price per share is valuated based on science rather than heavy influence from major indices and economic news around the world.

The Burrill Report submits: Human Genome Sciences (HGSI) said its experimental drug mapatumumab in combination with the chemotherapy agents paclitaxel and carboplatin failed in a mid-stage trial as a first-line therapy in advanced non-small cell lung cancer. The company said the combination including its drug showed no difference in disease response or progression-free survival compared to the control group. The study showed mapatumumab was well tolerated.

M.E. Garza submits: On Monday, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), officially announced additional positive safety data from its ongoing LibiGel® Phase III clinical development program.

The Burrill Report submits:

M.E. Garza submits: Late Friday afternoon, Clinical Data (CLDA) received news from the FDA that Viibryd (vilazodone HCl tablets) had been approved for patients with major depressive disorder. This is overwhelmingly positive news for the bulls of CLDA, but also for the whole biotech industry.

Mike Havrilla submits:Griffin Securities issued an updated research report today on ImmunoCellular Therapeutics (IMUC.OB), which includes a price objective of $3.25 per share.

The Burrill Report submits: The long road to approval for Mannkind's (MNKD) Afrezza inhaled insulin got a little longer March 15, as the FDA asked for more information to support its review of the drug. Afrezza is a powdered insulin for helping adult patients with type 1 and type 2 diabetes mellitus control high blood glucose, also known as hyperglycemia, which is a major cause of diabetes-related complications. An FDA decision on the drug was initially expected by January 16.

Jeremy Richards submits:Recent accomplishments for Avanir (AVNR) marked the most exciting quarter in the history of the company, and it is highly likely that big news is on the near-term horizon. Avanir’s share price closed at $2.67, a gross undervaluation, in Friday's trading session.